

# Bernard Zinman Cm

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2414078/bernard-zinman-cm-publications-by-year.pdf>  
**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

|                    |                          |                 |                 |
|--------------------|--------------------------|-----------------|-----------------|
| 254<br>papers      | 37,683<br>citations      | 72<br>h-index   | 193<br>g-index  |
| 268<br>ext. papers | 46,005<br>ext. citations | 11.4<br>avg, IF | 7.24<br>L-index |

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 254 | Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.. <i>EClinicalMedicine</i> , <b>2022</b> , 43, 101240  | 11.3 | 1         |
| 253 | The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.. <i>Diabetes and Metabolism</i> , <b>2022</b> , 101331   | 5.4  | 0         |
| 252 | Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.. <i>Diabetes Care</i> , <b>2022</b> , 45, 357-364  | 14.6 | 2         |
| 251 | Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 135-141  | 6.7  | 6         |
| 250 | Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2022</b> , 8, e12268 | 6    | 1         |
| 249 | Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.. <i>Diabetes Research and Clinical Practice</i> , <b>2022</b> , 109837   | 7.4  | 1         |
| 248 | Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. <i>Circulation</i> , <b>2022</b> ,  | 16.7 | 8         |
| 247 | Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.. <i>Circulation</i> , <b>2021</b> ,  | 16.7 | 3         |
| 246 | Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , <b>2021</b> ,   | 3.7  | 5         |
| 245 | Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , <b>2021</b> , 233, 141-148                                       | 4.9  | 10        |
| 244 | The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1652-1659   | 6.7  | 3         |
| 243 | Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. <i>Cell Metabolism</i> , <b>2021</b> , 33, 740-747   | 24.6 | 6         |
| 242 | Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1085-1093  | 12.3 | 9         |
| 241 | Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1926-1935  | 6.7  | 0         |
| 240 | Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort. <i>Diabetes Care</i> , <b>2021</b> , 44, 1682-1691   | 14.6 | 2         |
| 239 | Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 2603-2607   | 3.7  | 4         |
| 238 | Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1886-1891   | 6.7  | 3         |

|     |  |      |    |
|-----|--|------|----|
| 237 | Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , <b>2021</b> , 14, 1164-1173  | 8.4  | 18 |
| 236 | Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , <b>2021</b> , 99, 750-762   | 9.9  | 33 |
| 235 | Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 569-580 | 6.7  | 7  |
| 234 | Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , <b>2021</b> , 99, 999-1009  | 8.9  | 23 |
| 233 | Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 226-236  | 4.5  | 1  |
| 232 | Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 384-395  | 6.9  | 12 |
| 231 | Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1173-1181  | 6.7  | 4  |
| 230 | Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. <i>Diabetologia</i> , <b>2021</b> , 64, 1235-1243   | 10.3 | 4  |
| 229 | Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020053  | 6    | 6  |
| 228 | Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 568-577   | 7.9  | 1  |
| 227 | Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2775-2784   | 6.7  | 2  |
| 226 | The discovery of insulin in Toronto: beginning a 100-year journey of research and clinical achievement. <i>Diabetologia</i> , <b>2021</b> , 64, 947-953  | 10.3 | 8  |
| 225 | Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042909   | 1.2  | 6  |
| 224 | Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1546-1552  | 14.6 | 38 |
| 223 | Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>American Journal of Hypertension</i> , <b>2020</b> , 33, 1092-1101  | 2.3  | 9  |
| 222 | Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 1128-1139   | 12.7 | 51 |
| 221 | Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,  | 5.6  | 8  |
| 220 | The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 895-897        | 4.3  | 12 |

|     |  |      |     |
|-----|--|------|-----|
| 219 | Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Journal of the American Society of Echocardiography</i> , <b>2020</b> , 33, 644-646          | 5.8  | 10  |
| 218 | Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1151-1156  | 6.7  | 6   |
| 217 | Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. <i>Diabetes</i> 2020;69:291-299. <i>Diabetes</i> , <b>2020</b> , 69, e7-e8   | 0.9  | 3   |
| 216 | Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. <i>Metabolism Open</i> , <b>2020</b> , 7, 100039   | 2.8  | 9   |
| 215 | Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2193-2198  | 6.7  | 5   |
| 214 | Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1207-1214  | 6.7  | 14  |
| 213 | The authors reply. <i>Kidney International</i> , <b>2020</b> , 97, 213-214   | 9.9  |     |
| 212 | Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1141-1150 | 6.7  | 9   |
| 211 | Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. <i>Diabetes Care</i> , <b>2020</b> , 43, 1157-1163   | 14.6 | 12  |
| 210 | Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1803-1812   | 14.6 | 20  |
| 209 | 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. <i>Diabetes</i> , <b>2020</b> , 69, 131-LB   | 0.9  | 1   |
| 208 | The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and B-cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,   | 5.6  | 6   |
| 207 | Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). <i>Diabetes Therapy</i> , <b>2020</b> , 11, 53-70   | 3.6  | 12  |
| 206 | Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c. <i>Circulation</i> , <b>2020</b> , 141, 407-410   | 16.7 | 62  |
| 205 | Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , <b>2020</b> , 141, 704-707  | 16.7 | 115 |
| 204 | Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 126-135   | 12.3 | 30  |
| 203 | Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 631-639  | 6.7  | 39  |
| 202 | The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 3007-3015  | 14.6 | 13  |

|     |   |      |     |
|-----|---|------|-----|
| 201 | Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3401   | 3.7  | 9   |
| 200 | Effects of Canagliflozin in Patients with Baseline eGFR . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 1705-1714  | 6.9  | 30  |
| 199 | Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 200  | 8.7  | 5   |
| 198 | Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 949-959                          | 18.1 | 14  |
| 197 | Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2335-2347   | 6.7  | 7   |
| 196 | Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2487-2492 | 6.7  | 11  |
| 195 | Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1829-1840  | 1.9  | 10  |
| 194 | Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 834-844  | 18.1 | 42  |
| 193 | Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e016976   | 6    | 21  |
| 192 | Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME. <i>Diabetes and Vascular Disease Research</i> , <b>2020</b> , 17, 1479164120975256  | 3.3  | 4   |
| 191 | Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). <i>Diabetes and Vascular Disease Research</i> , <b>2020</b> , 17, 1479164120970933   | 3.3  | 1   |
| 190 | Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 209-217   | 9.5  | 20  |
| 189 | Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Circulation</i> , <b>2019</b> , 140, 1693-1702  | 16.7 | 205 |
| 188 | SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. <i>Cell Metabolism</i> , <b>2019</b> , 30, 609-613  | 24.6 | 36  |
| 187 | Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 1930-1938   | 14.6 | 31  |
| 186 | Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 2262-2271  | 14.6 | 82  |
| 185 | Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1155-1166  | 27.4 | 245 |
| 184 | Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME trial. <i>Age and Ageing</i> , <b>2019</b> , 48, 859-866   | 3    | 34  |



|     |  |      |      |
|-----|--|------|------|
| 183 | Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, e53-e55   | 14.6 | 13   |
| 182 | Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, e42-e44   | 14.6 | 16   |
| 181 | Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 854-861  | 6.9  | 18   |
| 180 | Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005875  | 7.6  | 30   |
| 179 | INTERMITTENT INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES: EFFECTS ON HYPOGLYCEMIA, WEIGHT GAIN, AND QUALITY OF LIFE OVER 2 YEARS. <i>Endocrine Practice</i> , <b>2019</b> , 25, 899-907  | 3.2  | 2    |
| 178 | Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2192-2202  | 6.7  | 43   |
| 177 | Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , <b>2019</b> , 16, 577-581   | 3.3  | 10   |
| 176 | Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , <b>2019</b> , 96, 489-504 | 9.9  | 47   |
| 175 | Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1745-1751   | 6.7  | 15   |
| 174 | Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1625-1633                         | 6.7  | 14   |
| 173 | Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , <b>2019</b> , 139, 1458-1460   | 16.7 | 34   |
| 172 | Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2780-2782   | 15.1 | 19   |
| 171 | Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 356-367  | 18.1 | 102  |
| 170 | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 2295-2306   | 59.2 | 2060 |
| 169 | Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1706-1714                                     | 6.7  | 3    |
| 168 | Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1437-1444   | 6.7  | 9    |
| 167 | Serum Ferritin and Glucose Homeostasis in Women With Recent Gestational Diabetes. <i>Canadian Journal of Diabetes</i> , <b>2019</b> , 43, 567-572  | 2.1  | 3    |
| 166 | The Distribution of Fatty Acid Biomarkers of Dairy Intake across Serum Lipid Fractions: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort. <i>Lipids</i> , <b>2019</b> , 54, 617-627   | 1.6  | 2    |

|     |  |      |     |
|-----|--|------|-----|
| 165 | FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) IN A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34,   | 4.3  | 1   |
| 164 | Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2450-2458   | 6.7  | 6   |
| 163 | Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , <b>2019</b> , 140, 739-750  | 16.7 | 140 |
| 162 | Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 713-715   | 7.4  | 27  |
| 161 | Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 156   | 8.7  | 6   |
| 160 | Screening Glucose Challenge Test in Pregnancy Can Identify Women With an Adverse Postpartum Cardiovascular Risk Factor Profile: Implications for Cardiovascular Risk Reduction. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e014231  | 6    | 3   |
| 159 | Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort. <i>BMJ Open Diabetes Research and Care</i> , <b>2019</b> , 7, e000825   | 4.5  | 8   |
| 158 | Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , <b>2019</b> , 139, 351-361   | 16.7 | 103 |
| 157 | Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 69-79   | 27.4 | 562 |
| 156 | HbA <sub>1c</sub> , Insulin Resistance, and $\beta$ Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy. <i>Diabetes Care</i> , <b>2019</b> , 42, e1-e3  | 14.6 | 14  |
| 155 | Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 622-630  | 6.7  | 9   |
| 154 | Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , <b>2019</b> , 139, 1384-1395  | 16.7 | 115 |
| 153 | Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. <i>Molecular Metabolism</i> , <b>2019</b> , 20, 63-78  | 8.8  | 19  |
| 152 | Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. <i>European Heart Journal</i> , <b>2018</b> , 39, 363-370   | 9.5  | 171 |
| 151 | Two-year trial of intermittent insulin therapy vs metformin for the preservation of $\beta$ cell function after initial short-term intensive insulin induction in early type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1399-1407   | 6.7  | 16  |
| 150 | Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. <i>Diabetes Care</i> , <b>2018</b> , 41, 14-31  | 14.6 | 263 |
| 149 | Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 105-113  | 18.1 | 336 |
| 148 | Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINagliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 39 | 8.7  | 57  |

|     |   |      |     |
|-----|---|------|-----|
| 147 | Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME <sup>2</sup> . <i>Diabetologia</i> , <b>2018</b> , 61, 1522-1527   | 10.3 | 33  |
| 146 | DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , <b>2018</b> , 61, 58-65   | 10.3 | 98  |
| 145 | Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). <i>Diabetologia</i> , <b>2018</b> , 61, 48-57  | 10.3 | 101 |
| 144 | Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , <b>2018</b> , 137, 119-129  | 16.7 | 252 |
| 143 | Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. <i>Physiology</i> , <b>2018</b> , 33, 197-210  | 9.8  | 2   |
| 142 | Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME <sup>2</sup> trial. <i>Diabetologia</i> , <b>2018</b> , 61, 2155-2163 | 10.3 | 100 |
| 141 | Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes. <i>Journal of Lipid Research</i> , <b>2018</b> , 59, 1751-1762  | 6.3  | 5   |
| 140 | Rationale and design of the CAROLINA <sup>3</sup> - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. <i>BMC Neurology</i> , <b>2018</b> , 18, 7     | 3.1  | 20  |
| 139 | Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , <b>2018</b> , 138, 1605-1607                              | 16.7 | 20  |
| 138 | Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. <i>Diabetes Care</i> , <b>2018</b> , 41, 1783-1791   | 14.6 | 63  |
| 137 | How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 356-363  | 14.6 | 365 |
| 136 | Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2018</b> , 314, E287-E295                                  | 6    | 7   |
| 135 | Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. <i>Circulation</i> , <b>2018</b> , 137, 405-407   | 16.7 | 96  |
| 134 | Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, e4-e5  | 14.6 | 116 |
| 133 | Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , <b>2018</b> , 138, 1599-1601   | 16.7 | 16  |
| 132 | Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , <b>2018</b> , 41, 2560-2569  | 14.6 | 149 |
| 131 | Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , <b>2018</b> , 138, 2884-2894   | 16.7 | 50  |
| 130 | Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease". <i>Circulation</i> , <b>2018</b> , 138, 850-851 | 16.7 | 1   |



|     |  |      |      |
|-----|--|------|------|
| 129 | Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 2383-2392   | 3.6  | 13   |
| 128 | Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , <b>2018</b> , 138, 1904-1907  | 16.7 | 75   |
| 127 | Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 2755-2769   | 12.7 | 81   |
| 126 | Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME <sup>2</sup> randomised trial. <i>Diabetologia</i> , <b>2018</b> , 61, 1712-1723    | 10.3 | 58   |
| 125 | Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. <i>Circulation</i> , <b>2018</b> , 137, 2179-2183  | 16.7 | 52   |
| 124 | SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME <sup>2</sup> TRIAL. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i487-i487                      | 4.3  |      |
| 123 | Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 744-748  | 6.7  | 7    |
| 122 | Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 777-783  | 14.6 | 102  |
| 121 | Novel Diabetes Drugs and the Cardiovascular Specialist. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2646-2656   | 15.1 | 64   |
| 120 | Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 723-732  | 59.2 | 349  |
| 119 | Asymmetric dimethylarginine and arginine metabolites in women with and without a history of gestational diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 964-970   | 3.2  | 2    |
| 118 | Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , <b>2017</b> , 48, 1218-1225  | 6.7  | 86   |
| 117 | Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , <b>2017</b> , 187, 1-9   | 4.9  | 39   |
| 116 | Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 793-799   | 14.6 | 12   |
| 115 | Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2017;40:777-783. <i>Diabetes Care</i> , <b>2017</b> , 40, e165-e166 | 14.6 | 2    |
| 114 | Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 839-848   | 59.2 | 599  |
| 113 | Bladder cancer in the EMPA-REG OUTCOME trial. <i>Diabetologia</i> , <b>2017</b> , 60, 2534-2535  | 10.3 | 18   |
| 112 | Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1228-1239  | 59.2 | 1017 |

|     |  |      |      |
|-----|--|------|------|
| 111 | Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , <b>2017</b> , 40, 1302-1313  | 14.6 | 7    |
| 110 | Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , <b>2017</b> , 5, e000461   | 4.5  | 5    |
| 109 | Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 1756-1762                                  | 14.6 | 54   |
| 108 | Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk". <i>Stroke</i> , <b>2017</b> , 48, e256-e257  | 6.7  |      |
| 107 | Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 610-621 | 18.1 | 217  |
| 106 | Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?. <i>Canadian Journal of Diabetes</i> , <b>2017</b> , 41, 6-9  | 2.1  | 11   |
| 105 | The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , <b>2017</b> , 46, 462-472   | 4.6  | 149  |
| 104 | Treatment of Type 1 Diabetes Mellitus in Adults <b>2016</b> , 770-787.e4   |      |      |
| 103 | Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 1969-1977  | 6.9  | 69   |
| 102 | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 311-22   | 59.2 | 3606 |
| 101 | Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 323-34   | 59.2 | 1956 |
| 100 | Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , <b>2016</b> , 174, 103-10   | 4.9  | 70   |
| 99  | The Relationship Between Parathyroid Hormone and 25-Hydroxyvitamin D During and After Pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 1729-36  | 5.6  | 13   |
| 98  | Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. <i>Canadian Journal of Diabetes</i> , <b>2016</b> , 40, 50-7   | 2.1  | 20   |
| 97  | Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , <b>2016</b> , 4, e000270  | 4.5  | 27   |
| 96  | Traditional foods and 25(OH)D concentrations in a subarctic First Nations community. <i>International Journal of Circumpolar Health</i> , <b>2016</b> , 75, 31956  | 1.7  | 4    |
| 95  | Evaluation of Circulating Determinants of Beta-Cell Function in Women With and Without Gestational Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2683-91  | 5.6  | 33   |
| 94  | Maternal Serum Prolactin and Prediction of Postpartum $\beta$ Cell Function and Risk of Prediabetes/Diabetes. <i>Diabetes Care</i> , <b>2016</b> , 39, 1250-8  | 14.6 | 29   |

|    |   |      |      |
|----|---|------|------|
| 93 | LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 1140-50  | 1.9  | 10   |
| 92 | Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. <i>American Heart Journal</i> , <b>2016</b> , 179, 175-83                         | 4.9  | 51   |
| 91 | Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?. <i>Canadian Journal of Diabetes</i> , <b>2016</b> , 40, 379-381  | 2.1  | 1    |
| 90 | Diabetes: Steno-2 - a small study with a big heart. <i>Nature Reviews Endocrinology</i> , <b>2016</b> , 12, 692-694   | 15.2 | 6    |
| 89 | Longitudinal Associations of Phospholipid and Cholesteryl Ester Fatty Acids With Disorders Underlying Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2536-44  | 5.6  | 7    |
| 88 | Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1702-10  | 14.6 | 126  |
| 87 | Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 45-53   | 27.4 | 290  |
| 86 | Fetal sex and maternal risk of gestational diabetes mellitus: the impact of having a boy. <i>Diabetes Care</i> , <b>2015</b> , 38, 844-51   | 14.6 | 78   |
| 85 | Response to Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic $\beta$ cell function in early type 2 diabetes: the LIBRA trial. <i>Diabetes Care</i> 2014;37:3270-3278. <i>Diabetes Care</i> , <b>2015</b> , 38, e26                         | 14.6 |      |
| 84 | Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA <sup>®</sup> ). <i>Diabetes and Vascular Disease Research</i> , <b>2015</b> , 12, 164-74                                       | 3.3  | 182  |
| 83 | Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial. <i>Advances in Therapy</i> , <b>2015</b> , 32, 201-15 | 4.1  | 12   |
| 82 | Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , <b>2015</b> , 38, 793-800   | 14.6 | 82   |
| 81 | SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. <i>Diabetes and Vascular Disease Research</i> , <b>2015</b> , 12, 90-100   | 3.3  | 283  |
| 80 | Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 2987-95   | 5.6  | 12   |
| 79 | Sex of the baby and risk of gestational diabetes mellitus in the mother: a systematic review and meta-analysis. <i>Diabetologia</i> , <b>2015</b> , 58, 2469-75   | 10.3 | 48   |
| 78 | The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 3702-9   | 5.6  | 45   |
| 77 | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2117-28   | 59.2 | 6064 |
| 76 | Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 132-9   | 14.6 | 110  |

|    |  |      |     |
|----|--|------|-----|
| 75 | Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum. <i>Diabetologia</i> , <b>2015</b> , 58, 1354-62   | 10.3 | 12  |
| 74 | Associations of circulating 25(OH)D with cardiometabolic disorders underlying type 2 diabetes mellitus in an Aboriginal Canadian community. <i>Diabetes Research and Clinical Practice</i> , <b>2015</b> , 109, 440-9  | 7.4  | 11  |
| 73 | Erythropoietin and glucose homeostasis in women at varying degrees of future diabetic risk. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 26-31   | 3.2  | 3   |
| 72 | Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. <i>PLoS ONE</i> , <b>2015</b> , 10, e0141085   | 3.7  | 26  |
| 71 | Longitudinal changes in estimated and measured GFR in type 1 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 810-8  | 12.7 | 31  |
| 70 | Diabetes: Progress in reducing vascular complications of diabetes. <i>Nature Reviews Endocrinology</i> , <b>2014</b> , 10, 451-3   | 15.2 | 4   |
| 69 | Renal outcomes in patients with type 1 diabetes and macroalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 2342-50   | 12.7 | 63  |
| 68 | Liraglutide and the preservation of pancreatic $\beta$ cell function in early type 2 diabetes: the LIBRA trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 3270-8  | 14.6 | 89  |
| 67 | Blood pressure-lowering effects of incretin-based diabetes therapies. <i>Canadian Journal of Diabetes</i> , <b>2014</b> , 38, 364-71   | 2.1  | 29  |
| 66 | Prospective associations of vitamin D status with $\beta$ cell function, insulin sensitivity, and glycemia: the impact of parathyroid hormone status. <i>Diabetes</i> , <b>2014</b> , 63, 3868-79  | 0.9  | 41  |
| 65 | Glycemic variability in patients with early type 2 diabetes: the impact of improvement in $\beta$ cell function. <i>Diabetes Care</i> , <b>2014</b> , 37, 1116-23  | 14.6 | 45  |
| 64 | Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. <i>Lancet, The</i> , <b>2014</b> , 384, 2228-34   | 40   | 278 |
| 63 | Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2014</b> , 105, 88-95 | 7.4  | 38  |
| 62 | Delivery by Caesarean section and infant cardiometabolic status at one year of age. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2014</b> , 36, 864-869  | 1.3  | 1   |
| 61 | The diabetes control and complications trial/epidemiology of diabetes interventions and complications study: 30th anniversary presentations. <i>Diabetes Care</i> , <b>2014</b> , 37, 8  | 14.6 | 13  |
| 60 | Vitamin D and parathyroid hormone status in pregnancy: effect on insulin sensitivity, $\beta$ cell function, and gestational diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 4506-13                                      | 5.6  | 34  |
| 59 | Response to comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. <i>Diabetes Care</i> 2014;37:1076-1082. <i>Diabetes Care</i> , <b>2014</b> , 37, e225   | 14.6 |     |
| 58 | Response to comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. <i>Diabetes Care</i> 2014;37:1076-1082. <i>Diabetes Care</i> , <b>2014</b> , 37, e209   | 14.6 | 1   |

|    |  |      |     |
|----|--|------|-----|
| 57 | Oscar B. Crofford: Clinician, scientist, educator, advocate for people with diabetes, and godfather of diabetes control and complications trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 3139-42  | 14.6 | 0   |
| 56 | Cardiometabolic implications of postpartum weight changes in the first year after delivery. <i>Diabetes Care</i> , <b>2014</b> , 37, 1998-2006   | 14.6 | 54  |
| 55 | Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 1480-3   | 14.6 | 186 |
| 54 | Each degree of glucose intolerance in pregnancy predicts distinct trajectories of $\beta$ -cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. <i>Diabetes Care</i> , <b>2014</b> , 37, 3262-9   | 14.6 | 68  |
| 53 | Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). <i>Cardiovascular Diabetology</i> , <b>2014</b> , 13, 102  | 8.7  | 153 |
| 52 | Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. <i>Diabetes Care</i> , <b>2014</b> , 37, 1076-82   | 14.6 | 24  |
| 51 | Newer insulin analogs: advances in basal insulin replacement. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15 Suppl 1, 6-10   | 6.7  | 28  |
| 50 | Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 823-30.e5   | 4.9  | 162 |
| 49 | Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , <b>2013</b> , 1, 28-34   | 18.1 | 129 |
| 48 | Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , <b>2013</b> , 10, 289-301  | 3.3  | 119 |
| 47 | Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naïve patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2013</b> , 1, 123-31 | 18.1 | 32  |
| 46 | Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. <i>Diabetes</i> , <b>2013</b> , 62, 3976-86   | 0.9  | 162 |
| 45 | Determinants of reversibility of $\beta$ -cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2013</b> , 305, E1398-407   | 6    | 36  |
| 44 | Fasting capillary glucose as a screening test for ruling out gestational diabetes mellitus. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2013</b> , 35, 515-522  | 1.3  | 9   |
| 43 | Predictors and clinical implications of a false negative glucose challenge test in pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2013</b> , 35, 889-898  | 1.3  | 3   |
| 42 | Insulins: past, present, and future. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2012</b> , 41, 1-24   | 5.5  | 28  |
| 41 | Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). <i>Diabetes Care</i> , <b>2012</b> , 35, 2464-71   | 14.6 | 263 |
| 40 | Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2366-76  | 59.2 | 390 |



|    |   |      |      |
|----|---|------|------|
| 39 | Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. <i>American Journal of Medicine</i> , <b>2011</b> , 124, S19-34  | 2.4  | 54   |
| 38 | Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. <i>Lancet, The</i> , <b>2011</b> , 377, 924-31                            | 4.0  | 107  |
| 37 | Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. <i>Archives of Internal Medicine</i> , <b>2011</b> , 171, 412-20  |      | 238  |
| 36 | Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. <i>Diabetes Care</i> , <b>2011</b> , 34, 1601-4                             | 14.6 | 23   |
| 35 | Prospective associations of vitamin D with $\beta$ -cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. <i>Diabetes</i> , <b>2011</b> , 60, 2947-53  | 0.9  | 103  |
| 34 | Effect of Rosiglitazone and Ramipril on $\beta$ -cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. <i>Diabetes Care</i> , <b>2010</b> , 33, 608-13  | 14.6 | 43   |
| 33 | Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. <i>Diabetes Care</i> , <b>2010</b> , 33, 1536-43 | 14.6 | 207  |
| 32 | Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 134-42   | 5.6  | 138  |
| 31 | Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. <i>Lancet, The</i> , <b>2010</b> , 376, 103-11   | 4.0  | 178  |
| 30 | Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 3824-32  | 5.6  | 58   |
| 29 | Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). <i>Diabetes Care</i> , <b>2009</b> , 32, 1224-30   | 14.6 | 691  |
| 28 | Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. <i>Obesity</i> , <b>2008</b> , 16, 1901-7   | 8    | 243  |
| 27 | Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. <i>Diabetes</i> , <b>2008</b> , 57, 995-1001  | 0.9  | 340  |
| 26 | Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i> , <b>2008</b> , 31, 845-51   | 14.6 | 431  |
| 25 | Does an intensive multifactorial intervention reduce mortality in type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2008</b> , 4, 434-5  |      |      |
| 24 | The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2007</b> , 146, 477-85  | 8    | 343  |
| 23 | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2427-43  | 59.2 | 2332 |
| 22 | Efficacy and Safety of Inhaled Insulin Therapy. <i>Annals of Internal Medicine</i> , <b>2006</b> , 144, 533   | 8    | 0    |

|    |  |      |      |
|----|--|------|------|
| 21 | Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2643-53  | 59.2 | 3690 |
| 20 | Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?. <i>Diabetes Care</i> , <b>2005</b> , 28, 600-6   | 14.6 | 287  |
| 19 | Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. <i>Diabetes</i> , <b>2004</b> , 53, 3193-200   | 0.9  | 124  |
| 18 | PPAR $\alpha$ agonists in type 2 diabetes: how far have we come in preventing the inevitable? A review of the metabolic effects of rosiglitazone. <i>Diabetes, Obesity and Metabolism</i> , <b>2001</b> , 3, 34-43           | 6.7  | 28   |
| 17 | The pharmacokinetics of insulin analogues and pumps. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , <b>2001</b> , 18, S3-S4  |      | 2    |
| 16 | Insulins today and beyond. <i>Lancet, The</i> , <b>2001</b> , 358, 739-46  | 40   | 312  |
| 15 | PPAR $\gamma$ agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. <i>Diabetes, Obesity and Metabolism</i> , <b>2001</b> , 3 Suppl 1, 34-43 | 6.7  |      |
| 14 | Overweight among children and adolescents in a Native Canadian community: prevalence and associated factors. <i>American Journal of Clinical Nutrition</i> , <b>2000</b> , 71, 693-700                                       | 7    | 184  |
| 13 | Common and rare ABCA1 variants affecting plasma HDL cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 1983-9  | 9.4  | 113  |
| 12 | Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers. <i>Journal of Human Genetics</i> , <b>1999</b> , 44, 10-4  | 4.3  | 49   |
| 11 | The ADD1 G460W polymorphism is not associated with variation in blood pressure in Canadian Oji-Cree. <i>Journal of Human Genetics</i> , <b>1999</b> , 44, 225-9  | 4.3  | 11   |
| 10 | -6A promoter variant of angiotensinogen and blood pressure variation in Canadian Oji-Cree. <i>Journal of Human Genetics</i> , <b>1998</b> , 43, 37-41  | 4.3  | 21   |
| 9  | Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. <i>Clinical Genetics</i> , <b>1998</b> , 54, 394-9  | 4    | 19   |
| 8  | Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 3373-7         | 5.6  | 72   |
| 7  | Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. <i>Hypertension</i> , <b>1997</b> , 29, 1073-7   | 8.5  | 32   |
| 6  | Body image concepts differ by age and sex in an Ojibway-Cree community in Canada. <i>Journal of Nutrition</i> , <b>1996</b> , 126, 2990-3000   | 4.1  | 40   |
| 5  | Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. <i>Clinical Science</i> , <b>1996</b> , 90, 189-95  | 6.5  | 88   |
| 4  | The physiologic replacement of insulin. An elusive goal. <i>New England Journal of Medicine</i> , <b>1989</b> , 321, 363-70  | 59.2 | 110  |

- 3 The role of insulin in the metabolic response to exercise in diabetic man. *Diabetes*, **1979**, 28 Suppl 1, 76-81.9 45
- 2 Glucoregulation during moderate exercise in insulin treated diabetics. *Journal of Clinical Endocrinology and Metabolism*, **1977**, 45, 641-52 5.6 155
- 1 Alternative Routes of Insulin Delivery 2